MAPT and Alzheimer disease: Interestingly, plasma brain-derived tau (BD-Tau) level, rather than T-Tau, has been suggested to represent an AD-specific neurodegenerative biomarker associated with clinical disease severity, as demonstrated by the strong association between BD-Tau concentrations in plasma and CSF [93].